US4511353A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Intravenous system for delivering a beneficial agent
Assignee: Alza Corp
•
Filing: 1981-10-09
•
Granted: 1985-04-16
•
Expires: 2001-10-09
Abstract
Abstract A formulation chamber is disclosed comprising a wall surrounding a lumen containing a device for delivering a beneficial agent. The chamber has an inlet for admitting a fluid into the chamber and an outlet for letting an agent formulation leave the chamber. The chamber is adapted for use in an intravenous delivery system for delivering an agent formulation to a patient.
Inventors
- 👤 Felix Theeuwes
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 18:01
CPC Classifications
A; A61; A61M; A61M5/00; A61M5/14; A61M5/1407
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
166 words
A self-contained, self-powered beneficial, drug delivery system for use with an intravenous delivery system, the beneficial drug delivery system, comprising in combination: (a) an intravenous formulation chamber comprising: a wall provided with an inlet that lets an intravenously acceptable medical fluid into the intravenous formulation chamber, and with an outlet for letting fluid leave the chamber; and, (b) a drug delivery device in the intravenous formulation chamber, the device comprising an inner mass transfer conductor; a beneficial intravenously administrable drug in an amount for performing a therapeutic program with said intravenously administrable drug in the conductor that is permeable to the passage of the drug; and, a membrane surrounding the conductor, which membrane release the drug in a therapeutically effective amount from the device into the medical fluid that is a pharmaceutically acceptable carrier for the drug and enters the intravenous, formulation chamber for formulating an intravenously administrable fluid drug formulation in situ that produces a beneficial effect, when administered intravenously to a recipient, over time.
Claim 2
Dependent Claim
166 words
A self-contained, self-powered beneficial, drug delivery system for use with an intravenous delivery system, the beneficial drug delivery system, comprising in combination: (a) an intravenous formulation chamber comprising: a wall provided with an inlet that lets an intravenously acceptable medical fluid into the intravenous formulation chamber, and with an outlet for letting fluid leave the chamber; and, (b) a drug delivery device in the intravenous formulation chamber, the device comprising an inner mass transfer conductor; a beneficial intravenously administrable drug in an amount for performing a therapeutic program with said intravenously administrable drug in the conductor that is permeable to the passage of the drug; and, a membrane surrounding the conductor, which membrane release the drug in a therapeutically effective amount from the device into the medical fluid that is a pharmaceutically acceptable carrier for the drug and enters the intravenous, formulation chamber for formulating an intravenously administrable fluid drug formulation in situ that produces a beneficial effect, when administered intravenously to a recipient, over time.
Claim 3
Dependent Claim
53 words
The beneficial drug delivery system for use with the intravenous delivery system according to claim 1, wherein when the chamber is connected to an intravenous delivery system, the device delivers the drug at a rate controlled by the device into the medical fluid that flows from the intravenous system into the formulation chamber.
Claim 4
Dependent Claim
24 words
The beneficial drug delivery system for use with the intravenous delivery system according to claim 1, wherein the mass transfer conductor is a solid.
Claim 5
Dependent Claim
24 words
The beneficial drug delivery system for use with the intravenous delivery system according to claim 1, wherein the mass transfer conductor is a liquid.
Claim 6
Dependent Claim
34 words
The beneficial drug delivery system for use with the intravenous delivery system according to claim 1, wherein the membrane is a release rate controlling membrane that release the drug by the process of diffusion.
Claim 7
Dependent Claim
23 words
The beneficial drug delivery system for use with the intravenous delivery system according to claim 1, wherein the delivery device membrane is microporous.
References Cited (Backward Citations)
US3305446A
Cited
CH497181A
Cited
US3512525A
Cited
US3854480A
Cited
US3797494A
Cited
US3993073A
Cited
US3995631A
Cited
US3760984A
Cited
US3948254A
Cited
US3845770A
Cited
US3921636A
Cited
US4177256A
Cited
US3941126A
Cited
US3993072A
Cited
US4217894A
Cited
US4193403A
Cited
US4233973A
Cited
US4306556A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-04-15 | 1988-10-15 | 1989-04-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-04-15 | 1992-10-15 | 1993-04-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-04-15 | 1996-10-15 | 1997-04-16 | $7700.00 | Window Closed / Lapsed |